Upregulated expression of DDX5 predicts recurrence and poor prognosis in breast cancer
Upregulated expression of DDX5 predicts recurrence and poor prognosis in breast cancer
复制标题
DDX5表达上调可预测乳腺癌复发和不良预后
DOI：
10.1016/j.prp.2021.153736
复制
发表时间：
2021-12-16
影响因子：
2.8
通讯作者：
Lin, Ping
中科院分区：
文献类型：
--
作者：
Li, Kai;Zhao, Gang;Lin, Ping
死亡盒解旋酶5（DDX 5）已被证明促进肿瘤发生和癌症进展。然而，DDX 5和乳腺癌（BC）患者复发之间的关系仍然未知。本研究的目的是评估DDX 5与BC患者的无复发生存期（RFS）和乳腺癌特异性生存期（BCSS）的相关性。免疫组化法检测DDX 5的表达。通过Kaplan-Meier生存分析计算RFS。通过考克斯比例风险模型评估单变量和多变量相关性。在本研究中，共分析了868例BC患者，我们发现DDX 5蛋白在BC组织中的表达显著高于邻近的正常组织。DDX 5升高与BC患者的侵袭性表型相关。此外，DDX 5蛋白在复发患者中比非复发患者上调，并且DDX 5蛋白水平与BC患者中更差的RFS和BCSS呈正相关。DDX 5高表达的BC患者年龄大于50岁，临床分期或组织学分级晚期，复发风险显著增加，生存期缩短。我们的研究结果强调了DDX 5在BC患者复发和临床结局中的重要性，并表明DDX 5可能是BC患者的潜在预测生物标志物。
DEAD-box helicase 5 (DDX5) has been shown to promote tumorigenesis and cancer progression. However, the relationship between DDX5 and recurrence in breast cancer (BC) patients remains unknown. The objective of the present study was to evaluate the correlation of DDX5 with recurrence-free survival (RFS) and breast cancerspecific survival (BCSS) in patients with BC. The expression of DDX5 was examined by immunohistochemical analysis. RFS was calculated by Kaplan-Meier survival analysis. Univariate and multivariable associations were assessed by Cox proportional hazards models. In the present study, a total of 868 BC patients were analysed, and we found that DDX5 protein was significantly overexpressed in BC tissues compared to adjacent normal tissues. Elevated DDX5 was associated with an aggressive phenotype in BC patients. Moreover, DDX5 protein was upregulated in recurrent patients compared with nonrecurrent patients, and DDX5 protein levels were positively associated with worse RFS and BCSS in BC patients. High DDX5 expressing BC patients with age more than 50 year, advanced clinical stage or histological grade had a significantly increased risk of recurrence and shorter survival. Our findings highlight the significance of DDX5 in the recurrence and clinical outcome of BC patients and suggest that DDX5 may be a potential predictive biomarker for patients with BC.